Brii Biosciences (FRA:7SS) Marketable Securities: €161.59 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7SS Brii Biosciences Ltd FRA:7SS
33 GF Score
Price €0.11
! 1 Warning Sign
View Full Analysis

What is Brii Biosciences Marketable Securities?

Brii Biosciences FRA:7SS 33 Marketable Securities is €161.59 Mil as of Dec. 2025. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Brii Biosciences's Marketable Securities for the quarter that ended in Dec. 2025 was €161.59 Mil.

Brii Biosciences's annual Marketable Securities declined from Dec. 2023 (€278.82 Mil) to Dec. 2024 (€172.74 Mil) and declined from Dec. 2024 (€172.74 Mil) to Dec. 2025 (€161.59 Mil).

Brii Biosciences  (FRA:7SS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Brii Biosciences Marketable Securities Related Terms

Brii Biosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Brii Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brii Biosciences Marketable Securities Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 69.43 244.65 278.82 172.74 161.59

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 278.82 221.60 172.74 68.49 161.59
FRA:7SS
33GF Score
Brii Biosciences Ltd FRA:7SS
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brii Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €161.59 Mil mean?
Brii Biosciences (FRA:7SS) has a Marketable Securities of €161.59 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Brii Biosciences and its competitors.
Is Brii Biosciences' Marketable Securities too high?
Brii Biosciences' current Marketable Securities is €161.59 Mil. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' Marketable Securities compare to VRTX and REGN?
Brii Biosciences' Marketable Securities of €161.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Brii Biosciences and its competitors. Brii Biosciences's current Marketable Securities is €161.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current Marketable Securities of €161.59 Mil. The current Marketable Securities is €161.59 Mil. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current Marketable Securities is €161.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brii Biosciences Business Description

Address No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score

Get the complete analysis for FRA:7SS

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price